Windham Venture Partners is a New York City, New York based venture capital firm. They invest in healthcare companies, with an emphasis on medical technology and digital health.
When they invest, they look for a company to have an experienced and knowledgeable leadership team, an evidence-based technology or procedure which approaches a problem in a new or superior way without intellectual property barriers and a concept past development stage, addressing a large market with impressive data and a clear value proposition.
Windham Venture Partners has made investments in NovellusDx, MC10, Nebula Genomics, Earlens Corporation, Nuvaira, NeuSpera Medical, CVRx, CredSimple, SubjectWell, Science Exchange, Blueprint Health, Cartiva, Coravin and Cureatr.
Nebula Genomics is a genetics company developing a platform for individuals to get their personal genome sequenced, and then enable them to store and control that information through cryptographic encryption on the blockchain.
A technology company offering research and development services focused on cardiovascular disease.
Personal Genome Diagnostics is a Baltimore-based molecular diagnostics company developing genomic testing and diagnostic kits.
NovellusDx is an Israel-based biotechnology company developing live-cell based assays to monitor signalling pathways.
Neuspera Medical is a San Jose, California-based medical device company.
Earlens Corporation is a Menlo Park, California-based company.
Subjectwell is an Austin, Texas-based company in the pharmaceuticals industry founded in 2012.
Adam E. Fine
General Partner & CEO
Lorne Taichman, MD, PhD
Director, Science & Technology
Roger S. Fine
General Partner & Chairman